Colorectal

Bayer to Highlight New Research at ASCO GI 2019 Cancers Symposium

(Bayer U.S.) Jan 16, 2019 - Bayer will present new data from its continued research on Stivarga® (regorafenib) in metastatic colorectal cancer (mCRC) and metastatic biliary tract cancers, and Nexavar® (sorafenib) in advanced liver cancer, at the 2019 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on January 17-19 in San Francisco.

read corporate press release

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer

(Array BioPharma) Jan 14, 2019 - Array BioPharma Inc. today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor and ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).

read corporate press release

USPSTF Begins New Review for Colorectal Cancer Screening

(Medscape Medical News) Jan 11, 2019 - Two issues are at stake: will the age to begin screening be lowered to 45 years? Will the new review prompt Medicare to pay for CT colonography?

read article (free registration required)

Study Identifies Novel Genetic Factors For Colorectal Cancer Risk

(VUMC Reporter/Vanderbilt University) Jan 10, 2019 - A large-scale study conducted among East Asians and led by Vanderbilt researchers has identified multiple, previously unknown genetic risk factors for colorectal cancer.

read article

Liver Transplant Patients Have Higher Prevalence of Colon Cancer and Non-Hodgkin Lymphoma

(Loyola University Medical Center) Jan 10, 2019 - Liver transplant patients over time experience an increasing trend toward colon cancer and non-Hodgkin lymphoma, according to an award-winning study led by a Loyola Medicine gastroenterologist.

read press release

Hopkins Researchers ID New Biomarker for Colorectal Cancers

(Johns Hopkins Medicine) Jan 7, 2019 - Johns Hopkins researchers have identified a protein involved in cell proliferation and the development of new blood vessels that could serve as a marker for the early detection of colorectal cancers.

read press release

To Screen Or Not To Screen? That Is The Question

(UCCC/Colorado Cancer Blogs) Jan 3, 2019 - If more and more younger people, or different demographics of people, are being diagnosed with colon cancer and lung cancer, do the old screening guidelines still hold up?

read article

Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer

(NASDAQ) Dec 20, 2018 - Gritstone Oncology, Inc., a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GRANITE-001 for the treatment of colorectal cancer.

read article

Alliance Releases 2018 Young-Onset Colorectal Cancer Survey Report

(Colorectal Cancer Alliance) Dec 19, 2018 - Nearly three-quarters of young-onset colorectal cancer patients are diagnosed with an advanced stage of the disease, a significantly higher percentage than has been reported for their more mature peers, according to a report from the Colorectal Cancer Alliance.

read press release

Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

(The Business Journals) Dec 19, 2018 - Two studies to evaluate ARY-007 in combination with KEYTRUDA® (pembrolizumab) in checkpoint-resistant solid tumors.

read article

Kaiser Permanente JAMA Study Finds 10-Year Follow-up Interval After Negative Colonoscopies Is Associated with Reduced Risk of Colorectal Cancer and Mortality

(Kaiser Permanente) Dec 17, 2018 - Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study published today in JAMA Internal Medicine. “Our study shows that following a colonoscopy with normal findings, there is a reduced risk of developing and dying from colorectal cancer for at least 10 years,” said study leader Jeffrey Lee, MD, Kaiser Permanente gastroenterologist and research scientist at the Division of Research.

read press release

Researchers Develop First Ever Model for Patient-Specific Treatment of Appendix Cancer

(Wake Forest Baptist Health) Dec 6, 2018 - Scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM) have recently developed a process that may change the way cancer of the appendix is treated in the future.

read press release

First Patient Enrolled in Isofol's Pivotal Phase 3 AGENT Study in 1st Line Metastatic Colorectal Cancer

(Markets Insider) Dec 18, 2018 - Isofol Medical AB, today announced that the first patient has been enrolled in the pivotal Phase 3 AGENT clinical study evaluating arfolitixorin for the treatment of metastatic colorectal cancer (mCRC).

read article

CAP Program Empowers Pathologists to Lead Optimal Test Ordering

(CAP) Dec 11, 2018 - To help doctors navigate colorectal cancer testing and ensure that the proper tests are ordered on each patient, pathologists can turn to the newest module in the College of American Pathologists (CAP) Test Ordering Program: “Biomarkers in Colorectal Cancer.”

read press release

Loss Of Two Genes Drives A Deadly Form Of Colorectal Cancer, Reveals A Potential Treatment

(Sanford Burnham Prebys) Dec 11, 2018 - Scientists have identified that the loss of two genes drives the formation of serrated colorectal cancer—yielding potential biomarkers.

read article

Researchers Develop Personalized Medicine Tool for Inherited Colorectal Cancer Syndrome Risk

(HCI) Dec 10, 2018 - An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease.

read press release

Why Many Older Patients with Low Risk Still Want Colorectal Cancer Screenings

(University of Michigan Health) Dec 7, 2018 - A new study in JAMA Network Open finds nearly one-third of veterans who underwent recommended screening colonoscopies were uncomfortable with the idea of stopping these screenings when the personal benefit was expected to be low.

read article

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

(Celyad) Nov 30, 2018 - Topline data from alloSHRINK trial are expected in second half of 2019; company regains full development and commercialization rights to CYAD-101 from ONO Pharmaceutical for Japan, Korea and Taiwan.

read corporate press release

WVU Cancer Institute Studies New Treatment For Colorectal Cancer Using Novel Drug Combination

(WVU Today) Nov 28, 2018 - Once colorectal cancer invades another organ—the liver or lung, for instance—a cancer patient has about a 13 percent chance of living five more years.

read article

Screening For Colorectal Cancer Spares Male Patients From Intense Treatments

(Helsinki University [Finland]) Nov 21, 2018 - While screening for colorectal cancer did not, so far, reduce mortality, it did reduce the need for chemotherapy and emergency surgeries among male patients.

read press release
Next Page